Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $6

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.

HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.

Read at benzinga.com